Anticancer Therapeutic Strategies Targeting p53 Aggregation

p53 is a tumor suppressor protein that is mutated in more than 50% of cancer cases. When mutated, it frequently results in p53 oncogenic gain of function (GOF), resulting in a greater tendency to aggregate in the phase separation and phase transition pathway. GOFs related to p53 aggregation include...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferretti, Giulia D. S., Quarti, Julia, dos Santos, Gileno, Rangel, Luciana P., Silva, Jerson L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569952/
https://www.ncbi.nlm.nih.gov/pubmed/36232329
http://dx.doi.org/10.3390/ijms231911023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569952/
https://www.ncbi.nlm.nih.gov/pubmed/36232329
http://dx.doi.org/10.3390/ijms231911023

Ejemplares similares